| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/16/2003 | US20030013892 Production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids |
| 01/16/2003 | US20030013886 Such as (E)-1-(2-Pyridyl)-2-styryl-1H-benzimidazole; antiinflammatory and analgesic agents; prostaglandin inhibitors |
| 01/16/2003 | US20030013875 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 01/16/2003 | US20030013874 Non-opioid analgesics for chronic and acute pain; 1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione; modulation of the opioid and ORL I receptors; agonist or antagonist activity at the CNS mu, delta and kappa receptors greater than morphine |
| 01/16/2003 | US20030013772 Composition, synthesis and therapeutic applications of polyamines |
| 01/16/2003 | US20030013771 Concurrent administering with drug; side effect reduction; central nervous system disorders |
| 01/16/2003 | US20030013761 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 01/16/2003 | US20030013758 Wound healing agents; brain disorders; cardiovascular disorders; sleep disorders |
| 01/16/2003 | US20030013754 Antiinflamamtory agents |
| 01/16/2003 | US20030013745 Urazole compounds useful as anti-inflammatory agents |
| 01/16/2003 | US20030013740 Antidepressants |
| 01/16/2003 | US20030013739 Synergistic mixtures; side effect reduction |
| 01/16/2003 | US20030013734 Skin disorders, immunology diseases, wound healing agents, antiulcer agents |
| 01/16/2003 | US20030013733 Antihistamines, sleep disorders, central nervous system disorders |
| 01/16/2003 | US20030013730 Preventing diarrhea |
| 01/16/2003 | US20030013726 Sleep disorders; anxiolytic agents; muscle disease |
| 01/16/2003 | US20030013718 Phthalazine derivatives for treating inflammatory diseases |
| 01/16/2003 | US20030013716 Pyrazino-pyridazine derivatives as ligands for gaba receptors |
| 01/16/2003 | US20030013713 Compounds as PDE IV and TNF-inhibitors |
| 01/16/2003 | US20030013708 Therapeutic heterocyclic compounds |
| 01/16/2003 | US20030013704 Adamantane derivatives |
| 01/16/2003 | US20030013699 Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject |
| 01/16/2003 | US20030013692 Methods of treating neurological disorders |
| 01/16/2003 | US20030013691 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/16/2003 | US20030013687 Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors |
| 01/16/2003 | US20030013668 Antiarthritic agents; inflammatory bowel disease; multiple sclerosis |
| 01/16/2003 | US20030013645 Central nervous system disorders; Alzheimer's disease; Parkinson's disease |
| 01/16/2003 | US20030012831 Liquid-liquid extraction being carried out in the first stage at a pH-value of about 4; treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence. |
| 01/16/2003 | US20030012830 Acetone, a salicylate-based compound and an emollient. |
| 01/16/2003 | US20030012827 May be administered in a purified form, or as part of a larger molecule, such as a glyceride that may be mixed, which releases free fatty acid after ingestion |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012782 Method and composition for altering a T cell mediated pathology |
| 01/16/2003 | US20030012781 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012738 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | CA2521993A1 Crystalline forms of ¬r-(r*,r*)|-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-¬(phenylamino)carbonyl|-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 01/16/2003 | CA2490386A1 Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist |
| 01/16/2003 | CA2454613A1 Substituted anilinic piperidines as mch selective antagonists |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452874A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | CA2452872A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | CA2452686A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | CA2452609A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | CA2452603A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | CA2452597A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | CA2452590A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | CA2452501A1 Secreted proteins |
| 01/16/2003 | CA2452211A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives as gaba-a receptor ligands |
| 01/16/2003 | CA2451983A1 Compounds used to treat alcoholism |
| 01/16/2003 | CA2451749A1 Novel immunomodulating compounds |
| 01/16/2003 | CA2451738A1 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine |
| 01/16/2003 | CA2451606A1 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | CA2451092A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 01/16/2003 | CA2450857A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/16/2003 | CA2450502A1 Epf receptor assays, compounds and therapeutic compositions |
| 01/16/2003 | CA2450236A1 Phage displayed pdz domain ligands |
| 01/16/2003 | CA2448913A1 Sulfone containing bicyclic aromatic ring compounds, their preparation and use as nicotinic acetyl-chloine receptors |
| 01/16/2003 | CA2394010A1 Novel n-benzylpiperazine derivatives, their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275659A1 Novel physiologically active peptides and use thereof |
| 01/15/2003 | EP1275657A1 Peptide derivatives and medicinal compositions |
| 01/15/2003 | EP1275647A1 Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275646A1 Indolylpyrrole derivatives and cell death inhibitors |
| 01/15/2003 | EP1275644A1 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275641A2 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275638A1 Combination therapy for the treatment of immunological disorders |
| 01/15/2003 | EP1275388A1 Tnf- alpha inhibitors |
| 01/15/2003 | EP1275383A1 Modified release pharmaceutical composition containing Bupropion HCI as active substance |
| 01/15/2003 | EP1274852A2 Targeted vaccine delivery systems |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274841A2 Regulation of human cyslt2-like gpcr protein |
| 01/15/2003 | EP1274840A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 01/15/2003 | EP1274835A1 Human nim1 kinase |
| 01/15/2003 | EP1274729A2 G protein coupled receptor |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274711A1 New aza-indolyl derivatives |
| 01/15/2003 | EP1274710A2 Novel heteroaryl-diazabicycloalkanes |
| 01/15/2003 | EP1274709A1 Salts of bicyclic, n-acylated imidazo-3-amines and imidazo-5-amines |
| 01/15/2003 | EP1274707A1 Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them |
| 01/15/2003 | EP1274703A2 N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treament of central nervous system disorders |
| 01/15/2003 | EP1274701A1 Chemical compounds |
| 01/15/2003 | EP1274699A1 Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 01/15/2003 | EP1274697A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 01/15/2003 | EP1274694A1 Novel compounds |
| 01/15/2003 | EP1274691A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors |
| 01/15/2003 | EP1274687A1 1,2,3,4- tetrahydroisoquinoline derivatives |
| 01/15/2003 | EP1274675A1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
| 01/15/2003 | EP1274674A1 Choline derivatives for the treatment of alzheimer's disease |
| 01/15/2003 | EP1274444A1 Compounds for the treatment of psychiatric or substance abuse disorders |
| 01/15/2003 | EP1274437A1 Medical combinations comprising tiotropium and fluticasone proprionate |
| 01/15/2003 | EP1274428A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274425A1 Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor |
| 01/15/2003 | EP1274423A1 Medicine for treating traumatic brain injury and other neuronal disorders |
| 01/15/2003 | EP1274418A1 Methods of use of penicillamines for the treatment of conditions resulting from dna damage |
| 01/15/2003 | EP1274417A2 Treatment of movement disorders with metabotropic glutamate receptor antagonists |
| 01/15/2003 | EP1274415A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274413A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274411A1 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use |
| 01/15/2003 | EP1274407A2 Uses of ppar-gamma agonists in neutrophil-induced diseases |